PDF(Pubmed)
Abstract：
Steroid receptor coactivator-1 (SRC-1, also known as NCOA1) frequently functions as a transcriptional coactivator by directly binding to transcription factors and recruiting to the target gene promoters to promote gene transcription by increasing chromatin accessibility and promoting the formation of transcriptional complexes. In recent decades, various biological and pathological functions of SRC-1 have been reported, especially in the context of tumorigenesis. SRC-1 is a facilitator of the progression of multiple cancers, including breast cancer, prostate cancer, gastrointestinal cancer, neurological cancer, and female genital system cancer. The emerging multiorgan oncogenic role of SRC-1 is still being studied and may not be limited to only steroid hormone-producing tissues. Growing evidence suggests that SRC-1 promotes target gene expression by directly binding to transcription factors, which may constitute a novel coactivation pattern independent of AR or ER. In addition, the antitumour effect of pharmacological inhibition of SRC-1 with agents including various small molecules or naturally active compounds has been reported, but their practical application in clinical cancer therapy is very limited. For this review, we gathered typical evidence on the oncogenic role of SRC-1, highlighted its major collaborators and regulatory genes, and mapped the potential mechanisms by which SRC-1 promotes primary tumour progression.
摘要：
类固醇受体共激活因子-1(SRC-1,也称为NCOA1)通常通过直接与转录因子结合并募集到靶基因启动子以通过增加染色质可及性和促进转录复合物的形成来促进基因转录而发挥转录共激活因子的作用。近几十年来,已经报道了SRC-1的各种生物学和病理学功能，特别是在肿瘤发生的背景下。SRC-1是多种癌症进展的促进者，包括乳腺癌,前列腺癌,胃肠道癌,神经癌症,女性生殖系统癌症.SRC-1的新出现的多器官致癌作用仍在研究中，可能不仅限于产生类固醇激素的组织。越来越多的证据表明，SRC-1通过直接结合转录因子促进靶基因表达，这可能构成一种独立于AR或ER的新型共激活模式。此外,已经报道了用包括各种小分子或天然活性化合物的药物抑制SRC-1的抗肿瘤作用,但是它们在临床癌症治疗中的实际应用非常有限。对于这篇评论，我们收集了SRC-1致癌作用的典型证据，强调了它的主要合作者和调控基因，并绘制了SRC-1促进原发性肿瘤进展的潜在机制。
